Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of Chidamide and Tislelizumab in advanced non-small cell lung cancer

Trial Profile

Phase II study of Chidamide and Tislelizumab in advanced non-small cell lung cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tislelizumab (Primary) ; Tucidinostat (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 24 Oct 2023 Results (At data cut off Apr 22, 2023, n=19) presented at the 48th European Society for Medical Oncology Congress
  • 10 Jul 2023 New trial record
  • 06 Jun 2023 Results (n=20; At the data cut-off February 10, 2023) assessing the efficacy and safety of chidamide plus tislelizumab combined with chemotherapy in advanced NSCLC, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top